



Coronaviruses are pleomorphic, single-stranded RNA viruses 
that measure 100–160 nm in diameter. Coronaviruses that 
infect humans fall into two genera: Alphacoronavirus and 
Betacoronavirus.[1] Severe acute respiratory syndrome 
coronaviruses (SARS-CoV-1 and SARS-CoV-2) and Middle 
East respiratory syndrome coronavirus are Betacoronaviruses. 
The coronavirus disease-2019 (COVID-19) is a public health 
emergency of international concern and is responsible for 
the ongoing pandemic.[2,3] The COVID-19 is caused by a 
novel SARS-CoV-2 that emerged in December 2019 from 
Wuhan, China.[4] The clinical presentation is often that of 
respiratory infection with a symptom severity ranging from 
a mild common cold-like illness to severe viral pneumonia, 
leading to acute respiratory distress syndrome that is potentially 
fatal. Patients manifesting with a severe form of the disease 
constitute approximately 15% of the cases, often among those 
with advanced age ≥62 years or underlying medical conditions, 
such as renal impairment, diabetes mellitus, asthma, obesity, 
and cardiovascular or cerebrovascular diseases.[5] In addition 
to other symptomatology, approximately 10%–12% of patients 
with COVID‑19 experience gastrointestinal (GI) symptoms, 
such as diarrhea (7.4%) and nausea or vomiting (4.6%). The 
GI manifestation of COVID-19 is a recognized feature and 
may portend a worse outcome for patients infected with 
SARS-CoV-2.[6] Several studies have provided insight into the 
ongoing COVID-19 pandemic with burgeoning information 
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being reported in a short time span, with a focus on the GI tract 
due to COVID-19.[5,6] To our knowledge, no study reported 
persistent vomiting as the only manifestation of COVID-19. 
It is against this background that we reported this case to 
highlight the unusual presentation of this disease.
case RePoRt
An 18-year-old undergraduate student presented with a 
three‑day history of persistent vomiting, which defied the 
antiemetic prescribed in the Medical Outpatient Department 
of Federal Medical Centre, Nguru. The vomiting was 
non-projectile and often postprandial, containing ingested food 
particles. Five days later, she started experiencing epigastric 
discomfort and postural dizziness and became lethargic.
Investigations done including full blood count and 
erythrocyte sedimentation rate, blood film for malaria 
parasite, urine microscopy, stool microscopy and parasitology, 
viral screening (HIV, hepatitis B and C), chest X-ray, 
abdominopelvic ultrasound scan, upper GI endoscopy, and 
abdominal, chest, and cranial computerized tomography were 
essentially normal. However, her nasopharyngeal and nasal 
swab sample tested positive for SARS-CoV-2 by polymerase 
chain reaction (PCR). The patient’s investigation result and 
laboratory parameters for normal Nigerian adults used as 
reference values are as presented in Table 1.
We placed her on the approved and/or trial medications 
for COVID-19 comprising lopinavir/ritonavir, zinc sulfate, 
hydroxychloroquine and azithromycin with Augmentin, 
vitamin C, metoclopramide and intravenous fluid for one week. 
She improved within 48 h of commencing therapy and became 
asymptomatic after 72 h. Repeat PCR after 12 days returned 
negative for SARS-CoV-2.
Table 1: Laboratory and imaging profile of the patient
Investigations Patient result Reference range[7]
Hematology
Hemoglobin concentration (g/dl) 11.3 11-13.5





Platelets numbers 250×109/L 150-400×109/L
Erythrocyte sedimentation rate (mm/h) 18 10-20
Malaria parasite (thin and thick film) Not seen -
Hepatitis B surface antigen Nonreactive -
Hepatitis C virus antibody Nonreactive -
HIV screening by determine and unigold Nonreactive -
Nasopharyngeal and nasal swab sample test for COVID 19 Positive for SARS CoV-2 by PCR
Widal agglutination reaction No significant titer of O, H Ag Significant level O and H Ag>1:160
Urinary pregnancy test Negative -
Urine microscopy Normal finding
Urine analysis Normal finding
Stool microscopy and parasitology Normal finding






Urea (mmol/L) 3.9 2.5-5.8
Creatinine 58 umol/L 44-132 mmol/L
Calcium (mmol/L) 2.4 2.2-2.7
Ionized calcium (mmol/L) 1.2
Ing. phosphate (mmol/L) 0.7 0.6-1.3
Albumin (mmol/L) 43 35-50
Upper gastrointestinal endoscopy The whole esophagus, stomach up to the duodenum, was visualized. The esophagus and 
gastric and duodenal mucosa appeared normal devoid of ulcer, tumor or narrowing
Cranial, thoracic and abdominal CT Normal finding
Chest X-ray (PA) view Normal finding
Abdominopelvic ultrasound Normal finding
CT: Computerized tomography, PA: Posteroanterior, COVID: Coronavirus disease, PCR: Polymerase chain reaction, HPF: High power field
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This case report highlights the unusual clinical feature of 
COVID-19. It, therefore, underscores the need to thoroughly 
investigate symptomatic patients and also to optimize standard 
precaution as potentially infectious diseases such as COVID-19 
may “masquerade” as a vague constitutional symptom(s).
dIscussIon
The most common clinical presentation of COVID 19 
involves the respiratory system. The spectrum of symptom 
severity ranges from features of mild common cold-like 
illness to severe viral pneumonia, which could lead to acute 
respiratory distress syndrome that is potentially associated 
with high mortality.[8] In addition to pulmonary involvement, 
SARS-CoV-2, the causative agent of COVID-19, is also 
associated with extrapulmonary manifestations.[9] The 
extrapulmonary pathology of COVID‑19 could be due to either 
extrapulmonary dissemination of the virus and its replication, 
as has been observed for other zoonotic coronaviruses 
or widespread immunopathological complications of the 
disease. Several studies have reported COVID-19 presenting 
with GI, neurologic, hematologic, cardiovascular, renal, and 
otolaryngologic manifestations.[5,6,8,9]
The incidence of GI manifestation has ranged from 12% to 
61% in patients with COVID-19.[10,11] In a meta-analysis of 29 
studies, the pooled prevalence of individual symptoms reported 
anorexia (21%), nausea and/vomiting (7%), diarrhea (9%), 
and abdominal pain (3%).[12] In a study from the USA, a 
higher prevalence of GI symptoms was reported (anorexia, 
34.8%; diarrhea, 33.7%; and nausea, 26.4%).[13] Furthermore, 
a study has shown that the presence of GI symptoms at 
presentation to be associated with a 70% increased risk of 
detection of SARS-CoV-2.[14] However, GI bleeding was 
rarely observed in the study, despite the presence of traditional 
risk factors, including prolonged mechanical ventilation, 
thrombocytopenia, or use of systemic anticoagulation.[14]
The pathophysiologic basis of GI involvement or damage in 
COVID-19 is multifactorial. The SARS-CoV-2–mediated direct 
damage to the GI cell is a possibility.[15-17] The Angiotensin-
converting enzyme 2 (ACE-2), the receptor of SARS-CoV-2, 
is highly expressed in some segments of gastrointestinal 
tract. The SARS-COV-2 nucleocapsid protein is detectable 
in gastric, duodenal, rectal, and glandular enterocytes.[18] 
The microvascular small bowel injury occurs due to diffuse 
endothelial inflammation in the submucosal vessels. Evidence 
for the inflammation-mediated injury is provided by the 
presence of infiltrating plasma cells and lymphocytes. 
Inflammatory changes and interstitial edema are also seen in 
the lamina propria of the stomach, duodenum, and rectum of 
patients.[19] A study by Mak et al. has postulated that changes 
in the composition of intestinal flora by the SARS‑CoV‑2 
may lead to GI symptoms and severe disease progression.[20] 
The gastrointestinal cells tropism for SARS-CoV-2 is further 
supported by the isolation of live virus from the stool samples 
of the patients with COVID-19. The continued shedding of 
infectious SARS-CoV-2 in the fecal matter suggests the need 
to investigate feces even after recovery as a potential source 
of viral transmission.[18]
Although there were no signs and symptoms attributable to 
neurological manifestation in our patient, Li et al. reported 
that some patients with COVID-19 showed neurological signs 
such as headache, nausea, and vomiting. However, it remains 
unclear if SARS-CoV-2 induces short-term manifestations of 
long term neurologic complications.[21]
The patient involved in this case report presented with 
persistent vomiting as the only manifestation of COVID-19, 
devoid of other symptomatology. There were no other 
abnormal findings on physical examination, except features 
of dehydration after persistent vomiting. Her laboratory 
parameters, including imaging and endoscopy findings, were 
essentially normal. The atypical presentation of COVID-19 
reported in this study seeks to provide insights into the less 
common manifestations of COVID-19. This study underscores 
the desirability of considering COVID‑19 as a differential 
diagnosis in patients even in the absence of a respiratory 
system. In a resource-limited setting, patients presenting with 
vague symptoms should be prioritized for testing.
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